Results 111 to 120 of about 17,592 (206)

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

Process for the preparation of Palbociclib

The present disclosure provides a process for the preparation of controlled particle size and specific surface area of crystalline form-A of Palbociclib and its process for the preparation. Palbociclib is represented by the following structural formula-1.
, MSN Laboratories Private Limited, R&D Center; Srinivasan Thirumalai Rajan; . Irukuvajjula Venkata Subrahmanya Vithal, Kesari Sai Manoj Krishna and Bhatraju Daveedu
core  

Graph‐Theoretical Approach for Predicting Physicochemical Properties of Stiff‐Person Syndrome Drugs

ChemistryOpen, Volume 15, Issue 6, June 2026.
Graph‐theoretical descriptors derived from M‐polynomials are integrated with quantitative structure–property relationship modeling and machine learning to uncover structure–property relationships of drugs used in stiff‐person syndrome. Strong correlations between degree‐based topological indices and key physicochemical properties are revealed ...
Jabbar Ali, Yasir Ali, Maher Ali Malik, Yilun Shang   +3 more
wiley   +1 more source

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Cell Death Discovery
Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation.
Cui Chen, Zehong Chen, Jinze Zhao, Xinyun Wen, Hanming Yao, Zijin Weng, Huiping Xiong, Zongheng Zheng, Juekun Wu   +8 more
doaj   +1 more source

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

Phytotherapy Research, Volume 40, Issue 6, Page 3171-3189, June 2026.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou, Jingyun Chi, Yuan Ding, Zhidi Zhang, Rui Liang, Tianhao Wang, Yan Jiang, Rujun Song, Huazhou Fu, Xizhen Zhou   +9 more
wiley   +1 more source

Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins

Palbociclib is a dual inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Palbociclib has frequently been studied in breast cancer cells and has also been linked to function of P-glycoprotein (P-gp), main protein responsible for cancer drug ...
Yalcin, Gizem Damla, Kazan, Hasan Huseyin, Gündüz, Ufuk, MUTLU, PELİN   +3 more
core   +1 more source

The Aging Microenvironment Shapes Angiogenic Remodeling in IBD‐Associated Colorectal Carcinogenesis

Aging Cell, Volume 25, Issue 6, June 2026.
In IBD, chronic inflammation promotes cellular senescence across epithelial, stromal, endothelial, and immune compartments. The resulting SASP drives pathological angiogenesis, vascular dysfunction, hypoxia, and immune suppression, thereby facilitating progression from inflammation to dysplasia and colitis‐associated colorectal cancer.
Ruoshu Duan, Qingyu Chen, Yuan Xu, Ye Yan, Sujing Jiang   +4 more
wiley   +1 more source

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer

Breast Cancer Research
Background Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways.
Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm, Geoffrey L Greene   +7 more
doaj   +1 more source

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

Cancer Science, Volume 117, Issue 6, Page 1623-1634, June 2026.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda   +17 more
wiley   +1 more source

Utilization of Healthy Volunteers in Oncology Drug Development in Japan: A 10‐Year Analysis of Approved Anticancer Agents (2014–2024)

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Anticancer agents with favorable safety profiles, such as immunomodulators and molecular‐targeted agents, are increasingly used in recent cancer therapy, and clinical trials for these agents increasingly incorporate healthy volunteers as well as cancer patients.
Kana Morihisa, Hiroyuki Yoshitsugu, Hirokazu Wakuda, Naoto Uemura   +3 more
wiley   +1 more source